Pre-therapeutic Biomarkers for Ranibizumab Therapy among Type 2 Diabetic Patients with Diabetic Macular Edema
CONCLUSIONS
The present study postulates that diffuse diabetic macular edema with proliferative diabetic retinopathy and baseline circulatory soluble VEGF receptor 2 may be potential candidates as therapy-stratifying markers for ranibizumab treatment among patients with diabetic macular edema.
Source: Optometry and Vision Science - Category: Opthalmology Tags: ORIGINAL INVESTIGATIONS Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Lucentis | Opthalmology | Ranibizumab Injection | Science | Study